Treating hepatitis C: current standard of care and emerging direct‐acting antiviral agents

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

2002 • 6,505 citations

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

2001 • 6,133 citations

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

2009 • 3,503 citations

Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line

1999 • 2,796 citations

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

2005 • 2,741 citations

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

2011 • 2,514 citations

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

2011 • 2,404 citations

Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

1998 • 2,112 citations

Binding of Hepatitis C Virus to CD81

1998 • 2,042 citations

The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002

2006 • 1,978 citations

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

2011 • 1,612 citations

Telaprevir for Retreatment of HCV Infection

2011 • 1,559 citations

The global burden of hepatitis C

2009 • 1,377 citations

Replication of hepatitis C virus

2007 • 1,308 citations

Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry

2007 • 1,182 citations

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

2009 • 1,176 citations

Epidemiology of hepatitis C

1997 • 1,112 citations

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

2010 • 926 citations

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

1996 • 675 citations

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

2012 • 598 citations

Hepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis

2006 • 563 citations

Cellular Binding of Hepatitis C Virus Envelope Glycoprotein E2 Requires Cell Surface Heparan Sulfate

2003 • 476 citations

Cyclophilin B Is a Functional Regulator of Hepatitis C Virus RNA Polymerase

2005 • 442 citations

Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study

2006 • 401 citations

Regulation of Hepatitis C Virion Production via Phosphorylation of the NS5A Protein

2008 • 394 citations

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

2007 • 383 citations

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

2010 • 330 citations

The Hepatitis C Virus Life Cycle as a Target for New Antiviral Therapies

2007 • 315 citations

An Interplay between Hypervariable Region 1 of the Hepatitis C Virus E2 Glycoprotein, the Scavenger Receptor BI, and High-Density Lipoprotein Promotes both Enhancement of Infection and Protection against Neutralizing Antibodies

2005 • 283 citations

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C

2007 • 258 citations

The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences

2003 • 251 citations

Changing trends in hepatitis C-related mortality in the United States, 1995-2004

2008 • 230 citations

The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients

2009 • 227 citations

Hepatitis C virus proteins

2007 • 184 citations

DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A

2010 • 182 citations

Hepatitis C Virus Particles and Lipoprotein Metabolism

2005 • 173 citations

Incidence and Transmission Patterns of Acute Hepatitis C in the United States, 1982-2006

2011 • 167 citations

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

2008 • 166 citations

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

2009 • 142 citations

Hepatitis B and hepatitis C in 2009

2009 • 137 citations

Early steps of the hepatitis C virus life cycle

2008 • 136 citations

Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection

2010 • 121 citations

Inosine Triphosphate Protects Against Ribavirin-Induced Adenosine Triphosphate Loss by Adenylosuccinate Synthase Function

2011 • 115 citations

Hepatitis C virus infection in Western Europe

1999 • 110 citations

Antiviral resistance and specifically targeted therapy for HCV (STAT‐C)

2009 • 99 citations

IL28B Genomic-Based Treatment Paradigms for Patients With Chronic Hepatitis C Infection: The Future of Personalized HCV Therapies

2010 • 95 citations

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR

2010 • 73 citations

Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study

2010 • 63 citations

Review: New direct-acting antivirals in the development for hepatitis C virus infection

2010 • 59 citations

Direct-acting antiviral medications for chronic hepatitis C virus infection.

2011 • 58 citations

4 ONCE DAILY ALISPORIVIR (DEB025) PLUS PEGIFNALFA2A/RIBAVIRIN RESULTS IN SUPERIOR SUSTAINED VIROLOGIC RESPONSE (SVR24) IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT NAIVE PATIENTS

2011 • 56 citations

61 ONCE DAILY PSI-7977 PLUS PEGIFN/RBV IN A PHASE 2B TRIAL: RAPID VIROLOGIC SUPPRESSION IN TREATMENT-NAIVE PATIENTS WITH HCV GT2/GT3

2011 • 47 citations

1359 FIRST SVR DATA WITH THE NUCLEOSIDE ANALOGUE POLYMERASE INHIBITOR MERICITABINE (RG7128) COMBINED WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE HCV G1/4 PATIENTS: INTERIM ANALYSIS FROM THE JUMP-C TRIAL

2011 • 45 citations

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients

2011 • 43 citations

60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION

2011 • 38 citations

Safety and Antiviral Activity of MK-5172, a Novel HCV NS3/4a Protease Inhibitor with Potent Activity Against Known Resistance Mutants, in Genotype 1 and 3 HCV-Infected Patients

2010 • 33 citations

66 SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/R

2011 • 30 citations

1376 THE ASPIRE TRIAL: TMC435 IN TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE-1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGIFN/RBV TREATMENT

2011 • 29 citations

Potential treatment options and future research to increase hepatitis C virus treatment response rate

2010 • 28 citations

Novel Hepatitis C Drugs in Current Trials

2008 • 23 citations

1372 ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY

2011 • 22 citations

1056 MK-7009 SIGNIFICANTLY IMPROVES RAPID VIRAL RESPONSE (RVR) IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION

2009 • 21 citations

Management of recurrent hepatitis C following liver transplantation.

2010 • 19 citations

1236 MECHANISMS OF ISOLATED UNCONJUGATED HYPERBILIRUBINEMIA INDUCED BY THE HCV NS3/4A PROTEASE INHIBITOR BI201335

2011 • 18 citations

Review: Hepatitis C virus replication and potential targets for direct-acting agents

2010 • 15 citations

935 IDENTIFICATION AND CHARACTERIZATION OF VCH-222, A NOVEL POTENT AND SELECTIVE NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR

2009 • 15 citations

Hepatitis C virus experimental model systems and antiviral drug research

2010 • 13 citations

2012 VIROLOGICAL RESPONSE, SAFETY, AND PHARMACOKINETIC PROFILE FOLLOWING SINGLE- AND MULTIPLE-DOSE ADMINISTRATION OF ACH-0141625 PROTEASE INHIBITOR TO HEALTHY VOLUNTEERS AND HCV GENOTYPE-1 PATIENTS

2010 • 10 citations

1212 ACH-2928: A NOVEL HIGHLY POTENT HCV NS5A INHIBITOR WITH FAVORABLE PRECLINICAL CHARACTERISTICS

2011 • 9 citations

Molecular Virology of the Hepatitis C Virus: Implication for Novel Therapies

2005 • 7 citations

770 CHARACTERIZATION OF THE HEPATOSELECTIVE DISTRIBUTION OF ACH-1625, A POTENT, CLINICAL STAGE HCV NS3 PROTEASE INHIBITOR

2010 • 4 citations